Nutriventia, part of Inventia Healthcare, has announced the publication of a study on its branded turmeric ingredient, TurmXTRA 60N, in Clinical Pharmacology: Advances and Applications.
“This study is pivotal since it showcases the benefits of a small dose of TurmXTRA 60N, that in healthy subjects and as more people become active, a supplement that helps preserve knee structure and function we feel will be highly sought after,” said Anand Godbole, Inventia Assistant VP of marketing & strategy.
The 90-day, randomised, double-blind, placebo-controlled, clinical trial was conducted in 96 healthy adults who experienced chronic knee pain following physical exertion resulting in significant improvement in terms of joint comfort, mobility, and performance post physical exertion.
The participants reported significant and clinically relevant improvement in efficacy variables by day 45, measurement of which was done on various test parameters that evaluated various aspects of mobility of joints and perception of pain.
The authors concluded three-months of supplementation with 250 mg of TurmXTRA 60N, once daily, improved joint comfort and improved joint performance and mobility in healthy subjects with chronic knee pain.
The study is the final part of a clinical package which evolved from a preclinical study that reportedly established the ingredient’s 10 times higher bioavailability as compared to standard turmeric extract in an equal dose format. The company also carried out a pharmacokinetic study in healthy human subjects and established bioequivalence of a 250 mg dose of TurmXTRA60N to 1575 mg standard turmeric extract with 95% curcuminoids, it says.
